Five Firms Big Pharma Should Buy Next

Pharmaceutical companies still see riches in biotechnology. AstraZeneca's $15.6 billion deal to acquire MedImmune is only the latest example of their continuing willingness to pay high premiums (in this case, a 53% premium to where MedImmune was trading before it put itself up for sale) for future growth.
Yahoo Finance